CoronaVac's success is due to Butantan's extensive experience, says specialist in health surveillance
Publicado em:
01/01/1970
Knowledge in forming international partnerships, experience in conducting clinical studies and producing vaccines on an industrial scale were the pillars for CoronaVac's success in Brazil, says the manager of strategic partnerships and business development at Butantan, Tiago Rocca. This experience was key to start the vaccine production process in Brazil quickly and with quality.
Details about the scientific basis for the vaccine will be discussed at the CoronaVac Symposium, held by Butantan and Sinovac on the 7th, 8th and 9th of December. Online and free of charge, the event will bring together Brazilian researchers from different fields and specialists from the United States, Turkey, Chile, China and Spain.
Nós usamos cookies e outras tecnologias semelhantes em nossos sites para melhorar o desenvolvimento de conteúdo interessante para nossos visitantes. Ao utilizar nossos sites, você concorda com tal monitoramento.
